The following is the summary of “Extracellular vesicles metabolic changes reveals plasma signature in stage-dependent diabetic kidney disease” ”published in the November 2022 issue of Renal failure by Pan, et al.

Diagnosing diabetic kidney disease (DKD) early on has been a challenging subject for a long time. In order to evaluate the metabolites of plasma extracellular vesicles and select new biomarkers for the early diagnosis of DKD, the purpose of this study was to analyze the metabolomic characteristics of plasma extracellular vesicles (EVs) at various stages of diabetic kidney disease (DKD). Plasma samples were taken from a total of 78 patients, comprising 20 healthy controls, 20 patients with type 2 diabetes mellitus (T2DM), 18 patients with DKD stage III, and 20 patients with DKD stage IV. 

The total number of samples collected was 78. In addition, EVs were extracted to conduct metabolomics research. According to the findings, there are significant variations in EV metabolomics between T2DM patients who do not have DKD and patients who do have DKD. Additionally, there are changes in EV metabolomics between DKD patients and T2DM patients who do not have DKD. There were 10  metabolites that were significantly different from each other that were linked to the development and progression of DKD. 

Researchers found that the biomarkers uracil, LPC(O-18:1/0:0), sphingosine 1-phosphate, and 4-acetamido butyric acid all showed outstanding predictive performance as potential early biomarkers for DKD. Uracil, LPC(O-18:1/0:0), sphingosine 1-phosphate, and 4-acetamido butyric acid all showed promise as possible candidates for use as appropriate biomarkers in the early diagnosis of DKD. Unexpectedly, adding these 4 candidate metabolites together resulted in an improved capacity to predict DKD.